Open Access

Journal of Cardiac and Pulmonary Rehabilitation
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Card Pulm Rehabi 2023, Vol 7(2): 190
  • DOI: 10.4172/jcpr.1000190

Utilizing Nanotechnology-Based Drug Delivery to Target Eosinophils in Chronic Respiratory Diseases

Payal Patel*
Department of Cardiology, King George's Medical University, Lucknow, India
*Corresponding Author : Payal Patel, Department of Cardiology, King George's Medical University, Lucknow, India, Email: Payal.p@yahoo.com

Received Date: Feb 28, 2023 / Published Date: Mar 28, 2023

Abstract

Major chronic respiratory diseases (CRDs) include asthma, COPD, COVID-19, EGPA, lung cancer, and pneumonia. These diseases are responsible for a significant amount of morbidity and mortality and affect millions of people worldwide. These CRDs are diseases that can't be changed and affect different parts of the respiratory system. They have a big impact on people of all income levels. Eosinophils in the lungs have been linked to an increase in all of these CRDs. Eosinophils are essential immune mediators that play a role in the pathophysiology and homeostasis of various tissues. Interestingly, cellular processes that regulate airway hyper responsiveness, remodeling, mucus hyper secretion, and lung inflammation are linked to an elevated eosinophil level. In eosinophilmediated lung diseases, therefore, eosinophil is regarded as the therapeutic target. However, conventional treatments for CRDs include bronchodilators, antibiotics, and other anti-inflammatory medications. In any case, the improvement of protection from these remedial specialists after long haul utilization stays a test. However, recent advancements in nanotechnology have revealed the targeted nanocarrier approach, which has the potential to significantly enhance a therapeutic drug's pharmacokinetics. The nanocarrier system has the potential to specifically target eosinophils and the components that are associated with them in order to achieve promising results in the pharmacotherapy of CRDs.

Citation: Patel P (2023) Utilizing Nanotechnology-Based Drug Delivery to Target Eosinophils in Chronic Respiratory Diseases. J Card Pulm Rehabi 7: 190. Doi: 10.4172/jcpr.1000190

Copyright: © 2023 Patel P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top